| MAS |
Report |
Adjusted EPS |
BEAT |
pred ~$1.34 vs. cons $1.30 |
MEDIUM |
| MAS |
Report |
Revenue |
BEAT |
pred ~$2.11B vs. cons $2.08B |
MEDIUM |
| MAS |
Report |
Adjusted operating margin |
IN-LINE |
pred ~19.5% vs. cons 19.4% |
MEDIUM |
| MAS |
Guide |
Adjusted EPS |
UNCHANGED |
guide ~$4.20 midpoint vs. cons $4.22 (FY2026) |
MEDIUM |
| MAS |
Guide |
Revenue growth |
UNCHANGED |
guide ~+2.0% vs. cons +2.2% (FY2026) |
MEDIUM |
| MAS |
Guide |
Adjusted operating margin |
UNCHANGED |
guide ~17.0% vs. cons 17.1% (FY2026) |
HIGH |
| MAS |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.2% |
— |
MEDIUM |
| MAS |
Return |
5-day cumulative residual |
+0.5% (FADE) |
Q2 adjusted EPS of ~$1.34 vs. $1.30 consensus supports an initial gain, but an unchanged FY2026 midpoint of ~$4.20 vs. $4.22 consensus implies H2 EPS of ~$1.82 vs. ~$1.88 consensus; weaker out-period math should pull revisions down and fade most of the day-1 residual. |
MEDIUM |